Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials
Articolo
Data di Pubblicazione:
2012
Citazione:
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials / A. Lipton, K. Fizazi, A.T. Stopeck, D.H. Henry, J.E. Brown, D.A. Yardley, G.E. Richardson, S. Siena, P. Maroto, M. Clemens, B. Bilynskyy, V. Charu, P. Beuzeboc, M. Rader, M. Viniegra, F. Saad, C. Ke, A. Braun, S. Jun. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 48:16(2012 Nov), pp. 3082-3092.
Abstract:
Background: Patients with bone metastases from advanced cancer often experience skeletal-related events (SRE), which cause substantial pain and morbidity. Denosumab, a fully human monoclonal antibody that inhibits RANK Ligand (RANKL), is a novel bone-targeted agent with a distinct mechanism of action relative to the bisphosphonate zoledronic acid, for prevention of SRE. This pre-planned analysis evaluates the efficacy and safety of denosumab versus zoledronic acid across three pivotal studies. Methods: Patient-level data from three identically designed, randomised, double-blind, active-controlled, phase 3 trials of patients with breast cancer, prostate cancer, other solid tumours or multiple myeloma were combined. End-points included time to first SRE, time to first and subsequent (multiple) SRE, adverse events, time to disease progression and overall survival. Findings: Denosumab was superior to zoledronic acid in delaying time to first on-study SRE by a median 8.21 months, reducing the risk of a first SRE by 17% (hazard ratio, 0.83 [95% confidence interval (CI): 0.76-0.90]; P < 0.001). Efficacy was demonstrated for first and multiple events and across patient subgroups (prior SRE status; age). Disease progression and overall survival were similar between the treatments. In contrast to zoledronic acid, denosumab did not require monitoring or dose modification/withholding based on renal status, and was not associated with acute-phase reactions. Hypocalcaemia was more common for denosumab. Osteonecrosis of the jaw occurred at a similar rate (P = 0.13). Conclusion: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Bone metastasis; Denosumab; Skeletal-related events; Zoledronic acid; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Disease Progression; Female; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Cancer Research; Oncology
Elenco autori:
A. Lipton, K. Fizazi, A.T. Stopeck, D.H. Henry, J.E. Brown, D.A. Yardley, G.E. Richardson, S. Siena, P. Maroto, M. Clemens, B. Bilynskyy, V. Charu, P. Beuzeboc, M. Rader, M. Viniegra, F. Saad, C. Ke, A. Braun, S. Jun
Link alla scheda completa: